• P8RI peptide

P8RI peptide

Not For Human Use, Lab Use Only.

Cat.#: 318909

Size:
Optional Service: TFA RemovalWhat's this?

Special Price 128.3 USD

Availability: 1-2 weeks
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    P8RI peptide
  • Documents
  • Sequence Shortening
    kwpalfvr
  • Sequence
    H-kwpalfvr-OH
  • Length (aa)
    8
  • Peptide Purity (HPLC)
    95.2%
  • Molecular Formula
    C51H77N13O9
  • Molecular Weight
    1016.24
  • Source
    Synthetic
  • Form
    Powder
  • Description
    P8RI(CD31 agonist), a retro-inverso sequence of the best candidate identified by functional in vitro screening of a peptide library, passed an absorption, distribution, metabolism, excretion and toxicology analysis. The IC50 of P8RI based on the human ether-a-go-go-related gene tail current amplitude was 150 μg/ml, which represents an ≈40-fold Cmax of the drug in the plasma of subcutaneously injected mice. Of note, at the concentration of 5 μg/ml, which is higher than the Cmax in the blood after subcutaneous injection, the peptide has no effect on the tail amplitude of the potassium channel. P8RI significantly affected the polarization of macrophages, resulting in a dramatic reduction in M1 markers such as the expression of iNOS and arginase II and the production of IL-6, IL-12p70, and TNF-α, whereas it enhanced the M2 phenotype, as detected by an increased expression of arginase I and production of IL-10. Curative treatment with P8RI promotes the healing of experimental dissecting aneurysm in atherosclerotic mice.
  • Storage Guidelines
    Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual:Handling and Storage of Synthetic Peptides
  • References
    • Vigne, J., Bay, S., Aid-Launais, R. et al. Cleaved CD31 as a target for in vivo molecular imaging of inflammation. Sci Rep 9, 19560 (2019). https://doi.org/10.1038/s41598-019-56163-x
  • About TFA salt

    Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

    TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

    TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

    In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.

  • Molar Concentration Calculator

  • Dilution Calculator

  • Percent Concentration Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight

Peptide Services: NovoPro's peptide synthesis services include standard chemical peptide synthesis, peptide modification, peptide libraries, and recombinant peptide expression.

Standard Peptide Synthesis: NovoPro offers quality peptides at the most competitive prices in the industry, starting at $3.20 per amino acid. NovoPro provides PepBox – Automatic Quote Tool for online price calculation.

Peptide Modifications: NovoPro offers a wide range of peptide modification services including isotope labeling (2H, 15N, and 13C), multiple disulfide bonds, multiple phosphorylations, KLH, BSA, ovalbumin, amidation, acetylation, biotin, FITC, etc.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"